Nikolai Brun's guest appearances

Nikolai Brun

Vital Health Podcast

Ivor Cummins

Jeff Allen

Steve Rosenberg

Wilfred Reilly

John Murphy

John Doyle

Robert Madelin

Peter Young

Mark McClellan

Sarah Garner

Richard Evans

Chris Austin

Heidi Larson

Elin Haf Davies

John LaMattina

OwlTail

Nikolai Brun is a rare regulator who has rolled up his sleeves and successfully helped bring a therapy to market. He was part of a team at Genmab that discovered one of the first monoclonal antibodies for treating cancer.  Nikolai was previously the Chief Medical Officer (CMO) of the Danish Medicines Agency, and has recently gone back into industry, as the CMO of the Swedish biotech company, Affibody. In this Vital Health Podcast, Nikolai Brun outlines why Europe’s biopharmaceutical sector is falling behind the rest of the world's and how the proposed EU pharmaceutical legislation, while containing many good ideas, may harm the sector instead. The podcast also highlights how the continuing decline in clinical trials in the EU should be setting off alarm bells in Brussels, even if the reaction of many bureaucrats implies that they don’t see this as a concern or a priority. This podcast was made possible with the support of EFPIA - The European Federation of Pharmaceutical Industries and Associations. See omnystudio.com/listener for privacy information.

Nikolai Brun is a rare regulator who has rolled up his sleeves and successfully helped bring a therapy to market. He was part of a team at Genmab that discovered one of the first monoclonal antibodies for treating cancer.  Nikolai was previously the Chief Medical Officer (CMO) of the Danish Medicines Agency, and has recently gone back into industry, as the CMO of the Swedish biotech company, Affibody. In this Vital Health Podcast, Nikolai Brun outlines why Europe’s biopharmaceutical sector is falling behind the rest of the world's and how the proposed EU pharmaceutical legislation, while containing many good ideas, may harm the sector instead. The podcast also highlights how the continuing decline in clinical trials in the EU should be setting off alarm bells in Brussels, even if the reaction of many bureaucrats implies that they don’t see this as a concern or a priority. This podcast was made possible with the support of EFPIA - The European Federation of Pharmaceutical Industries and Associations. See <a href="https://omnystudio.com/listener" rel="nofollow" target="_blank">omnystudio.com/listener</a> for privacy information.

Nikolai Brun - Improving Europe's Biopharma Legislation

Duane Schulthess of Vital Transformation sits down at the DIA Global conference in Boston, for a one on one discussion with Nikolai Brun, CMO Danish Medicines Agency.See omnystudio.com/listener for privacy information.

Duane Schulthess of Vital Transformation sits down at the DIA Global conference in Boston, for a one on one discussion with Nikolai Brun, CMO Danish Medicines Agency.See <a href="https://omnystudio.com/listener" rel="nofollow" target="_blank">omnystudio.com/listener</a> for privacy information.

Nikolai Brun, CMO Danish Medicines Agency